A blood test that predicts lung cancer 5 years early? What we know so far
Researchers identified a blood-based protein signature in *Cell* that can predict lung cancer risk up to five years before diagnosis, involving 80,000+ samples and 80 scientists across four continents. The study suggests targeting inflammation linked to these proteins may reduce cancer risk, though further clinical trials are needed before implementation.
A team of over 80 scientists from the Francis Crick Institute and University College London discovered a blood test capable of predicting lung cancer risk years before diagnosis. Published in *Cell* on June 4, the study analyzed 48,000 UK Biobank blood samples, revealing 14 proteins linked to elevated cancer risk. When combined with factors like age, smoking history, and pre-existing lung conditions, the test outperformed existing risk assessments. The protein signature was validated across eight global datasets, including non-smokers in Taiwan, indicating broader applicability. The proteins signal inflammation in lung tissue rather than tumor presence, suggesting dormant cells are pushed toward malignancy. Researchers found that cigarette smoke and air pollution trigger this inflammatory pathway, supporting the idea that chronic inflammation and genetic mutations collaborate in cancer development. Experiments with cell and mouse models confirmed the link between these proteins and cancer progression. Lead researcher Roel Vermeulen noted the signature reflects an 'inflamed lung environment,' an early warning for malignancy. The findings challenge the notion that lung cancer stems solely from genetic mutations, emphasizing inflammation’s role. Experts like Dr. Charles Swanton (though not quoted fully) highlight the potential to shift focus from treatment to prevention, a long-elusive goal in oncology. While promising, the study’s authors stress the need for additional clinical trials before integrating the test into routine care. The discovery could revolutionize early intervention strategies, particularly for high-risk groups, though widespread use remains years away. The research underscores the importance of addressing pollution and inflammation as modifiable risk factors.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.